Evogene (EVGN) Earning Positive News Coverage, Report Shows

Media headlines about Evogene (NASDAQ:EVGN) have trended positive this week, according to Accern Sentiment. The research firm identifies negative and positive press coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of negative one to one, with scores closest to one being the most favorable. Evogene earned a media sentiment score of 0.31 on Accern’s scale. Accern also assigned news stories about the biotechnology company an impact score of 46.0009271079102 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Separately, ValuEngine raised Evogene from a “sell” rating to a “hold” rating in a report on Wednesday, May 2nd.

Shares of Evogene traded up $0.01, hitting $2.91, on Friday, MarketBeat Ratings reports. The company had a trading volume of 3,014 shares, compared to its average volume of 4,095. The stock has a market cap of $74.78 million, a PE ratio of -3.59 and a beta of 0.76. Evogene has a twelve month low of $2.66 and a twelve month high of $5.74.

Evogene (NASDAQ:EVGN) last announced its quarterly earnings results on Wednesday, February 28th. The biotechnology company reported ($0.24) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.21) by ($0.03). Evogene had a negative net margin of 616.33% and a negative return on equity of 27.15%. The business had revenue of $0.73 million during the quarter.

Evogene Company Profile

Evogene Ltd., a biotechnology company, focuses on the enhancement of crop productivity and performance in the United States and Germany. It operates through two segments, Evogene and Evofuel. The Evogene segment develops seed traits, ag-chemical products, and ag-biological products to enhance plant performance.

Insider Buying and Selling by Quarter for Evogene (NASDAQ:EVGN)

Receive News & Ratings for Evogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evogene and related companies with MarketBeat.com's FREE daily email newsletter.




Leave a Reply